Cumulative tenofovir exposure among patients with human immunodeficiency virus/hepatitis B co-infection with differential viral suppression.

Helen L ZhangMeredith MockLane BushmanPeter L AndersonJennifer J KiserSusanna Naggie

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

This case-control study explored cumulative tenofovir exposure among patients with HIV/HBV co-infection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n=4) compared to those with complete suppression (n=5) (516 vs.1456 fmol/punch).

Keyphrases

antiretroviral therapy
human immunodeficiency virus
hiv infected
hiv positive
hiv aids
hepatitis c virus
sars cov
hepatitis b virus
hiv testing
men who have sex with men
south africa